European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Giovanni B Frisoni; Cristina Festari; Federico Massa; Matteo Cotta Ramusino; Stefania Orini; Dag Aarsland; Federica Agosta; Claudio Babiloni; Barbara Borroni; Stefano F Cappa; Kristian S Frederiksen; Lutz Froelich; Valentina Garibotto; Alexander Haliassos; Frank Jessen; Anita Kamondi; Roy Pc Kessels; Silvia D Morbelli; John T O'Brien; Markus Otto; Armand Perret-Liaudet; Francesca B Pizzini; Mathieu Vandenbulcke; Ritva Vanninen; Frans Verhey; Meike W Vernooij; Tarek Yousry; Mercè Boada Rovira; Bruno Dubois; Jean Georges; Oskar Hansson; Craig W Ritchie; Philip Scheltens; Wiesje M van der Flier; Flavio Nobili

doi:10.1016/S1474-4422(23)00447-7

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Giovanni B Frisoni, Cristina Festari, Federico Massa, Matteo Cotta Ramusino, Stefania Orini, Dag Aarsland, Federica Agosta, Claudio Babiloni, Barbara Borroni, Stefano F Cappa, Kristian S Frederiksen, Lutz Froelich, Valentina Garibotto, Alexander Haliassos, Frank Jessen, Anita Kamondi, Roy Pc Kessels, Silvia D Morbelli, John T O'Brien, Markus OttoArmand Perret-Liaudet, Francesca B Pizzini, Mathieu Vandenbulcke, Ritva Vanninen, Frans Verhey, Meike W Vernooij, Tarek Yousry, Mercè Boada Rovira, Bruno Dubois, Jean Georges, Oskar Hansson, Craig W Ritchie, Philip Scheltens, Wiesje M van der Flier, Flavio Nobili

Department of Neurology

25 Citations (Scopus)

Abstract

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

Original language	English
Journal	The Lancet Neurology
Volume	23
Issue number	3
Pages (from-to)	302-312
Number of pages	11
ISSN	1474-4422
DOIs	https://doi.org/10.1016/S1474-4422(23)00447-7
Publication status	Published - Mar 2024

Keywords

Humans
Alzheimer Disease/diagnosis
Europe
Biomarkers
Consensus
Societies, Scientific

Access to Document

10.1016/S1474-4422(23)00447-7

Cite this

Frisoni, G. B., Festari, C., Massa, F., Cotta Ramusino, M., Orini, S., Aarsland, D., Agosta, F., Babiloni, C., Borroni, B., Cappa, S. F., Frederiksen, K. S., Froelich, L., Garibotto, V., Haliassos, A., Jessen, F., Kamondi, A., Kessels, R. P., Morbelli, S. D., O'Brien, J. T., ... Nobili, F. (2024). European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. The Lancet Neurology, 23(3), 302-312. https://doi.org/10.1016/S1474-4422(23)00447-7

Frisoni, GB, Festari, C, Massa, F, Cotta Ramusino, M, Orini, S, Aarsland, D, Agosta, F, Babiloni, C, Borroni, B, Cappa, SF, Frederiksen, KS, Froelich, L, Garibotto, V, Haliassos, A, Jessen, F, Kamondi, A, Kessels, RP, Morbelli, SD, O'Brien, JT, Otto, M, Perret-Liaudet, A, Pizzini, FB, Vandenbulcke, M, Vanninen, R, Verhey, F, Vernooij, MW, Yousry, T, Boada Rovira, M, Dubois, B, Georges, J, Hansson, O, Ritchie, CW, Scheltens, P, van der Flier, WM & Nobili, F 2024, 'European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders', The Lancet Neurology, vol. 23, no. 3, pp. 302-312. https://doi.org/10.1016/S1474-4422(23)00447-7

@article{1fdab945cc6c4ca9960bc1594cb4c861,

title = "European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders",

abstract = "The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.",

keywords = "Humans, Alzheimer Disease/diagnosis, Europe, Biomarkers, Consensus, Societies, Scientific",

author = "Frisoni, {Giovanni B} and Cristina Festari and Federico Massa and {Cotta Ramusino}, Matteo and Stefania Orini and Dag Aarsland and Federica Agosta and Claudio Babiloni and Barbara Borroni and Cappa, {Stefano F} and Frederiksen, {Kristian S} and Lutz Froelich and Valentina Garibotto and Alexander Haliassos and Frank Jessen and Anita Kamondi and Kessels, {Roy Pc} and Morbelli, {Silvia D} and O'Brien, {John T} and Markus Otto and Armand Perret-Liaudet and Pizzini, {Francesca B} and Mathieu Vandenbulcke and Ritva Vanninen and Frans Verhey and Vernooij, {Meike W} and Tarek Yousry and {Boada Rovira}, Merc{\`e} and Bruno Dubois and Jean Georges and Oskar Hansson and Ritchie, {Craig W} and Philip Scheltens and {van der Flier}, {Wiesje M} and Flavio Nobili",

year = "2024",

month = mar,

doi = "10.1016/S1474-4422(23)00447-7",

language = "English",

volume = "23",

pages = "302--312",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "The/Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

AU - Frisoni, Giovanni B

AU - Festari, Cristina

AU - Massa, Federico

AU - Cotta Ramusino, Matteo

AU - Orini, Stefania

AU - Aarsland, Dag

AU - Agosta, Federica

AU - Babiloni, Claudio

AU - Borroni, Barbara

AU - Cappa, Stefano F

AU - Frederiksen, Kristian S

AU - Froelich, Lutz

AU - Garibotto, Valentina

AU - Haliassos, Alexander

AU - Jessen, Frank

AU - Kamondi, Anita

AU - Kessels, Roy Pc

AU - Morbelli, Silvia D

AU - O'Brien, John T

AU - Otto, Markus

AU - Perret-Liaudet, Armand

AU - Pizzini, Francesca B

AU - Vandenbulcke, Mathieu

AU - Vanninen, Ritva

AU - Verhey, Frans

AU - Vernooij, Meike W

AU - Yousry, Tarek

AU - Boada Rovira, Mercè

AU - Dubois, Bruno

AU - Georges, Jean

AU - Hansson, Oskar

AU - Ritchie, Craig W

AU - Scheltens, Philip

AU - van der Flier, Wiesje M

AU - Nobili, Flavio

PY - 2024/3

Y1 - 2024/3

N2 - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

AB - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

KW - Humans

KW - Alzheimer Disease/diagnosis

KW - Europe

KW - Biomarkers

KW - Consensus

KW - Societies, Scientific

UR - http://www.scopus.com/inward/record.url?scp=85185269773&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(23)00447-7

DO - 10.1016/S1474-4422(23)00447-7

M3 - Review

C2 - 38365381

SN - 1474-4422

VL - 23

SP - 302

EP - 312

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 3

ER -

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this